Institut Mérieux SA is offering equity to a preferred partner via a restricted capital increase. Exor NV has consequently acquired 10% of Institut Mérieux’s capital by investing $850 million. A third of this new funding, some $285 million, will be injected immediately this summer, with the balance following over the coming 12 months.
Carmot Therapeutics Inc. has raised $160 million in series D financing to support a trio of early to midstage clinical programs focused on treating diabetes and obesity with peptide-based small-molecule incretin receptor modulators.
Frontera Therapeutics Inc. raised $160 million in a series B funding round to develop its lead gene therapy product candidate for retinal disease, FT-001, for which INDs have been approved by the U.S. FDA and China NMPA.
Cleerly Inc. sees a bright future ahead after boosting its fundraising to date nearly five-fold with a $192 million series C. The new infusion brought the total invested in the company to $248 million, a solid endorsement of a company that hopes to transform cardiology with precision-based diagnostics that move away from indirect indicators to accurate measurements.
Eurekare SA, a technology commercialization and investment firm, has opened the doors to the first of a number of biotech “studios” it is setting up to hothouse synthetic biology and microbiome companies formed around intellectual property sourced from universities across Europe. It’s the most recent step forward in Eurekare’s ambition of creating a pan-European network for identifying, selecting and nurturing high quality European science in these two fields, which in the opinion of the firm’s founders, is at the same time of very high quality and seriously under-exploited.
Forsight Robotics Ltd. amassed up to $55 million in series A financing led by Adani Group, with participation by existing investors Eclipse Ventures and Mithril Capital. The new funds will be used to further development of Forsight’s Oryom system, a surgical platform for fully robotic cataract surgery.
Frontera Therapeutics Inc. raised $160 million in a series B funding round to develop its lead gene therapy product candidate for retinal disease, FT-001, for which INDs have been approved by the U.S. FDA and China NMPA.
RSS
